Mapping the Peds QL ^TM 4.0 onto CHU-9D: a cross-sectional study in functional dyspepsia population from China.

Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE

Original Publication: Lausanne : Frontiers Editorial Office

Quality of Life* ; Dyspepsia*/epidemiology; Adolescent ; Humans ; Child ; Cross-Sectional Studies ; Child Health ; Surveys and Questionnaires ; China/epidemiology

Objective: The study aims to develop a mapping algorithm from the Pediatric Quality of Life Inventory™ 4. 0 (Peds QL 4.0) onto Child Health Utility 9D (CHU-9D) based on the cross-sectional data of functional dyspepsia (FD) children and adolescents in China.
Methods: A sample of 2,152 patients with FD completed both the CHU-9D and Peds QL 4.0 instruments. A total of six regression models were used to develop the mapping algorithm, including ordinary least squares regression (OLS), the generalized linear regression model (GLM), MM-estimator model (MM), Tobit regression (Tobit) and Beta regression (Beta) for direct mapping, and multinomial logistic regression (MLOGIT) for response mapping. Peds QL 4.0 total score, Peds QL 4.0 dimension scores, Peds QL 4.0 item scores, gender, and age were used as independent variables according to the Spearman correlation coefficient. The ranking of indicators, including the mean absolute error (MAE), root mean squared error (RMSE), adjusted R ² , and consistent correlation coefficient (CCC), was used to assess the predictive ability of the models.
Results: The Tobit model with selected Peds QL 4.0 item scores, gender and age as the independent variable predicted the most accurate. The best-performing models for other possible combinations of variables were also shown.
Conclusion: The mapping algorithm helps to transform Peds QL 4.0 data into health utility value. It is valuable for conducting health technology evaluations within clinical studies that have only collected Peds QL 4.0 data.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Wang, Wan, Li, Huang and Xi.)

Patient. 2020 Oct;13(5):537-555. (PMID: 32382953)
Value Health. 2005 Mar-Apr;8(2):94-104. (PMID: 15804318)
BMC Gastroenterol. 2021 May 12;21(1):218. (PMID: 33980172)
Clin Gastroenterol Hepatol. 2010 Jun;8(6):498-503. (PMID: 20304102)
Value Health. 2008 May-Jun;11(3):509-21. (PMID: 18179659)
Value Health. 2017 Jan;20(1):18-27. (PMID: 28212961)
Med Decis Making. 2006 Jul-Aug;26(4):401-9. (PMID: 16855128)
Health Qual Life Outcomes. 2013 May 30;11:87. (PMID: 23721407)
Eur J Health Econ. 2010 Apr;11(2):215-25. (PMID: 19585162)
Value Health. 2012 Dec;15(8):1084-91. (PMID: 23244811)
Pharmacoeconomics. 2017 Apr;35(4):453-467. (PMID: 27928758)
Pharmacoeconomics. 2018 Apr;36(4):451-465. (PMID: 29264866)
Med Decis Making. 2014 Oct;34(7):919-30. (PMID: 24025662)
Qual Life Res. 2020 Mar;29(3):639-652. (PMID: 31745690)
Zhonghua Er Ke Za Zhi. 2022 Aug 2;60(8):751-755. (PMID: 35922183)
PLoS One. 2014 Feb 20;9(2):e89222. (PMID: 24586607)
Health Technol Assess. 2014 Feb;18(9):1-224. (PMID: 24524660)
Qual Life Res. 2019 Jan;28(1):163-176. (PMID: 30374777)
Med Decis Making. 2012 Jan-Feb;32(1):56-69. (PMID: 22009667)
Qual Life Res. 2013 Feb;22(1):173-83. (PMID: 22302618)
Appl Health Econ Health Policy. 2022 Jan;20(1):119-131. (PMID: 34554442)
J Pediatr. 2018 Apr;195:134-139. (PMID: 29398057)
Value Health. 2012 May;15(3):550-61. (PMID: 22583466)
Gastroenterology. 2006 Apr;130(5):1527-37. (PMID: 16678566)
Qual Life Res. 2020 Sep;29(9):2529-2539. (PMID: 32297132)
J Clin Epidemiol. 1993 Dec;46(12):1417-32. (PMID: 8263569)
Qual Life Res. 2009 Oct;18(8):1105-13. (PMID: 19693703)
Eur J Health Econ. 2021 Sep;22(7):1083-1093. (PMID: 33893889)
Appl Health Econ Health Policy. 2011;9(1):15-27. (PMID: 21033766)
BMC Gastroenterol. 2018 Feb 27;18(1):33. (PMID: 29486708)
Gastroenterology. 2012 Apr;142(4):754-61. (PMID: 22226783)
J Pediatr. 2016 Oct;177:39-43.e3. (PMID: 27156185)
J Behav Med. 2002 Apr;25(2):175-93. (PMID: 11977437)
Pharmacoeconomics. 2015 Oct;33(10):1013-28. (PMID: 25985933)
PLoS One. 2015 May 20;10(5):e0126982. (PMID: 25992621)
Value Health. 2019 Feb;22(2):239-246. (PMID: 30711070)
Pharmacoecon Open. 2017 Dec;1(4):233-239. (PMID: 29441504)
Eur J Health Econ. 2021 Jul;22(5):735-747. (PMID: 33860379)
Pharmacoeconomics. 2015 Oct;33(10):993-1011. (PMID: 26232200)
Qual Life Res. 2023 Jul;32(7):1909-1923. (PMID: 36814010)
Qual Life Res. 2010 Oct;19(8):1229-33. (PMID: 20473781)
Pediatrics. 2013 Sep;132(3):475-82. (PMID: 23940244)
Value Health. 2013 Jan-Feb;16(1):202-10. (PMID: 23337232)
Medicine (Baltimore). 2021 Apr 2;100(13):e25426. (PMID: 33787652)
Qual Life Res. 2018 Nov;27(11):2823-2839. (PMID: 30173314)
Eur J Health Econ. 2019 Nov;20(8):1195-1206. (PMID: 31338698)
BMC Med Res Methodol. 2012 Sep 17;12:144. (PMID: 22984825)
BMC Gastroenterol. 2014 Aug 21;14:150. (PMID: 25145589)
Qual Life Res. 2022 May;31(5):1533-1544. (PMID: 34846671)

Keywords: CHU-9D; Peds QL 4.0; functional dyspepsia; health utility value; mapping

Date Created: 20230616 Date Completed: 20230619 Latest Revision: 20230619

20231215

PMC10266104

10.3389/fpubh.2023.1166760

37325313